Metabolomics in Diabetic Retinopathy: From Potential Biomarkers to Molecular Basis of Oxidative Stress
Diabetic retinopathy (DR), the leading cause of blindness in working-age adults, is one of the most common complications of diabetes mellitus (DM) featured by metabolic disorders. With the global prevalence of diabetes, the incidence of DR is expected to increase. Prompt detection and the targeting...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/11/19/3005 |
| _version_ | 1797480022162800640 |
|---|---|
| author | Qizhi Jian Yingjie Wu Fang Zhang |
| author_facet | Qizhi Jian Yingjie Wu Fang Zhang |
| author_sort | Qizhi Jian |
| collection | DOAJ |
| description | Diabetic retinopathy (DR), the leading cause of blindness in working-age adults, is one of the most common complications of diabetes mellitus (DM) featured by metabolic disorders. With the global prevalence of diabetes, the incidence of DR is expected to increase. Prompt detection and the targeting of anti-oxidative stress intervention could effectively reduce visual impairment caused by DR. However, the diagnosis and treatment of DR is often delayed due to the absence of obvious signs of retina imaging. Research progress supports that metabolomics is a powerful tool to discover potential diagnostic biomarkers and therapeutic targets for the causes of oxidative stress through profiling metabolites in diseases, which provides great opportunities for DR with metabolic heterogeneity. Thus, this review summarizes the latest advances in metabolomics in DR, as well as potential diagnostic biomarkers, and predicts molecular targets through the integration of genome-wide association studies (GWAS) with metabolomics. Metabolomics provides potential biomarkers, molecular targets and therapeutic strategies for controlling the progress of DR, especially the interventions at early stages and precise treatments based on individual patient variations. |
| first_indexed | 2024-03-09T21:54:10Z |
| format | Article |
| id | doaj.art-cbf4acb5b1e149938ceca7ea174536bf |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-09T21:54:10Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-cbf4acb5b1e149938ceca7ea174536bf2023-11-23T20:00:59ZengMDPI AGCells2073-44092022-09-011119300510.3390/cells11193005Metabolomics in Diabetic Retinopathy: From Potential Biomarkers to Molecular Basis of Oxidative StressQizhi Jian0Yingjie Wu1Fang Zhang2National Clinical Research Center for Eye Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, ChinaInstitute for Genome Engineered Animal Models of Human Diseases, National Center of Genetically Engineered Animal Models for International Research, Liaoning Provence Key Laboratory of Genome Engineered Animal Models, Dalian Medical University, Dalian 116000, ChinaNational Clinical Research Center for Eye Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, ChinaDiabetic retinopathy (DR), the leading cause of blindness in working-age adults, is one of the most common complications of diabetes mellitus (DM) featured by metabolic disorders. With the global prevalence of diabetes, the incidence of DR is expected to increase. Prompt detection and the targeting of anti-oxidative stress intervention could effectively reduce visual impairment caused by DR. However, the diagnosis and treatment of DR is often delayed due to the absence of obvious signs of retina imaging. Research progress supports that metabolomics is a powerful tool to discover potential diagnostic biomarkers and therapeutic targets for the causes of oxidative stress through profiling metabolites in diseases, which provides great opportunities for DR with metabolic heterogeneity. Thus, this review summarizes the latest advances in metabolomics in DR, as well as potential diagnostic biomarkers, and predicts molecular targets through the integration of genome-wide association studies (GWAS) with metabolomics. Metabolomics provides potential biomarkers, molecular targets and therapeutic strategies for controlling the progress of DR, especially the interventions at early stages and precise treatments based on individual patient variations.https://www.mdpi.com/2073-4409/11/19/3005diabetic retinopathymetabolomicsbiomarkersmetabolic pathwaymolecular targets |
| spellingShingle | Qizhi Jian Yingjie Wu Fang Zhang Metabolomics in Diabetic Retinopathy: From Potential Biomarkers to Molecular Basis of Oxidative Stress Cells diabetic retinopathy metabolomics biomarkers metabolic pathway molecular targets |
| title | Metabolomics in Diabetic Retinopathy: From Potential Biomarkers to Molecular Basis of Oxidative Stress |
| title_full | Metabolomics in Diabetic Retinopathy: From Potential Biomarkers to Molecular Basis of Oxidative Stress |
| title_fullStr | Metabolomics in Diabetic Retinopathy: From Potential Biomarkers to Molecular Basis of Oxidative Stress |
| title_full_unstemmed | Metabolomics in Diabetic Retinopathy: From Potential Biomarkers to Molecular Basis of Oxidative Stress |
| title_short | Metabolomics in Diabetic Retinopathy: From Potential Biomarkers to Molecular Basis of Oxidative Stress |
| title_sort | metabolomics in diabetic retinopathy from potential biomarkers to molecular basis of oxidative stress |
| topic | diabetic retinopathy metabolomics biomarkers metabolic pathway molecular targets |
| url | https://www.mdpi.com/2073-4409/11/19/3005 |
| work_keys_str_mv | AT qizhijian metabolomicsindiabeticretinopathyfrompotentialbiomarkerstomolecularbasisofoxidativestress AT yingjiewu metabolomicsindiabeticretinopathyfrompotentialbiomarkerstomolecularbasisofoxidativestress AT fangzhang metabolomicsindiabeticretinopathyfrompotentialbiomarkerstomolecularbasisofoxidativestress |